Importantly, the role of BRAF mutations seems negligible in the context of renal cell tumors [49], testicular germ cell tumors [50], as well as cervical, endometrial, and ovarian carcinomas [51], as per existing postulations [17]. This evidence concerns the gene BRAF and ovarian carcinoma.